Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled crossover trial of TOBI in cystic fibrosis patients colonized with Pseudomonas aeruginosa
2009-016590-15Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa lung colonization (PALC) (2 arms), sponsored by Novartis. Primary endpoint: Pseudomonas aeruginosa eradication at Day 29. Started Nov 2009; status: completed.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa lung colonization (PALC)
Beyond the preview
Go deeper on 2009-016590-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016590-15.